A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
NCT07185880
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
36
Enrollment
INDUSTRY
Sponsor class
Conditions
Glioblastoma (GBM)
Interventions
DRUG:
MT-125
Sponsor
Myosin Therapeutics Inc.
Collaborators
[object Object]
[object Object]